We are gathering various solutions from around the world to streamline Clinical Operations and Data Management, and accelerate Drug Development.

As illustrated below, our company offers a wide range of solutions that support the entire process of pharmaceutical and medical device development - from the early stages through regulatory submission. Our product lineup combines widely adopted core clinical development systems such as EDC and CTMS with cutting‑edge technologies designed to address longstanding challenges and shape the future of clinical operations.

The core solutions is the Clinflash® Cloud product suite from Clinflash, which covers nearly all operational needs in clinical development. In addition, through our partnership with Inventis, we provide globally standardized and properly managed devices for both patients and clinical sites, supporting services such as ePRO and eConsent device provisioning.

We also offer a range of advanced, AI‑driven solutions from companies including AiCure, Akyrian Systems, IhHandPlus, Kenosha AI, Saama, and Sequentia Biotech, helping our clients accelerate digital transformation and operational efficiency. Furthermore, to meet the growing demand for SaMD application development and distribution, we provide the Extra Horizon platform.

Beyond these IT solutions, our collaboration with Richmond Pharmacology in London enables us to support Phase I studies in the UK - including those involving Japanese participants - as well as provide access to facilities capable of conducting gene‑editing therapy trials. Through this expanded capability, we aim to further accelerate and streamline clinical development to address challenges such as drug lag and drug loss in Japan.

AiCure is a company that has been in the eClinical marketplace for 15 years, with its roots starting with funding from the US National Institutes of Health to research the use of artificial intelligence in patient care. At present, AiCure is seen as the leading resource in the world to address the issue of medication adherence in clinical trials. AiCure's product is a highly differentiated and patented system that uses computer vision and machine learning to make assessments of patient audio and video to provide determinations of patient behavior, such as protocol adherence. AiCure also uses its platform to assess audio and visual phenotypes of disease in the form of biomarkers used in research.

During COVID-19, with a growing demand for remote and decentralized solutions, AiCure was seen as a unique value because of its years of experience deploying and supporting patient-facing software. AiCure responded by developing compliant telemedicine solutions for its sponsors. Also, AiCure launched Clinical Site Services (CSS) to relieve technology burden at sites.

Today, AiCure continues to innovate and broaden its market presence as a platform for all things patient-facing. This includes eConsent, ePRO/eCOA, telemedicine, AI-driven patient engagement via two-way text, and of course, medication adherence and digital biomarkers.

AiCure has a proven record with dozens of clinical trials sponsored by the most prominent Big Pharma companies in the world. Its AI-platform has been deployed in over 40 languages. Importantly, AiCure has supported studies in all phases of drug development leading to FDA submissions, projects in post-marketing research, city- and state-wide deployments in public health, and large US Government and military contracts.

In 2015, a team with years of experience in building e-Clinical solutions decided to pursue the next frontier in clinical data capture. Noting that the flow of data from electronic health records (EHR) to electronic data capture (EDC) was still driven entirely by manual transcription, and frustrated that decades of integration efforts using interoperability standards were yet to yield ubiquitous results, the team set out to build a system that would enable frictionless data collection at clinical sites in a way that would be EHR-agnostic while re-imagining operational processes to eliminate time-consuming and wasteful habits for all stakeholders involved.

They created Akyrian Systems, and the result of years in R&D led to Akyrian’s flagship product, Source Data Extraction or SDE, a patented clinical data platform that is now poised to significantly reduce clinical trial duration and overall cost.

Clinflash Healthcare Technology (Jiaxing) Co., Ltd is a healthcare information technology company headquartered in Jiaxing, Zhejiang Province, People's Republic of China, providing cloud platforms and professional services for Clinical Development. Clinflash was founded in 2014. In 2018, it was recognized by the Chinese government as a national high-tech enterprise, and currently supports the development of innovative drugs, generic drugs, medical devices, in vitro diagnostics, etc. with over 12 product lines. It also supports international quality and industry standards such as ISO 9000, ISO 20000, ISO27001, ISO27701 certification, compliance with FDA 21 CFR Part 11 and CDISC standards. Clinflash offers high quality, robust and superior systems.

Services for Japanese customers are provided by the system within a cloud data center in Japan.

Extra Horizon N.V. was founded in 2022 as a spin-off from Qompium N.V., the home of FibriCheck. As one of the first CE Class IIa certified device agnostic Software as a Medical Device (SaMD) products, FibriCheck is widely recognized as a true pioneer in its field. The Extra Horizon certified cloud platform is one of the strengths that made this possible, and is now shared with the wider world of medical innovators as a pioneer in its own field.

By breaking the recurring barriers involved in building a MedTech solution, we help get digital health products to the people who need them as quickly as possible, improving the quality of healthcare and making a lasting impact.

InHandPlus is a healthcare science company that uses its proprietary smartwatches and AI to provide solutions that enable patients to solve medication adherence issues and detect and identify various diseases using the camera and motion sensors built into the smartwatch. The company is headquartered in Seoul and provides smartwatches and associated cloud-based software and AI to a wide range of global customers, mainly in Asia.

Specific examples include tracking medication, detecting scratching and tremors, recording each meal and calculating calories, and analyzing the effects of food. It is expected to be applied to clinical trials and research, as well as dietary advice and DCT.

Inventus is a unique vendor that provides devices specifically designed for use in clinical trials, serving both patients and clinical sites. These purpose built devices feature globally unified specifications and robust security, and are deployed in more than 70 countries with support for 586 languages. Optimized to support a broad range of eCOA data collection activities, including ePRO and eConsent, they help enhance patient engagement and ensure high data quality. The devices also deliver exceptional durability and reliability, meeting the clinical environment's demands for accuracy and connectivity.

Furthermore, Inventus offers “Inventus Connect,” a global eSIM platform available in more than 150 countries that greatly simplifies device connectivity management in clinical trials. Its carrier agnostic network architecture enables stable cross border data communication, supporting operational efficiency and cost optimization. In addition, the Inventus Device Management (IDM) software, purpose built for clinical trials, provides centralized control of device setup, OS updates, and security management, delivering a level of compliance and operational efficiency that general commercial devices cannot match.

Kenosha AI is a solution provider that offers cloud-based AI software that allows users to search for regulatory information related to pharmaceuticals in major countries (regions) in chat format, as well as consulting on how to create effective prompts and systems for linking with internal documents. The company is headquartered in San Francisco and provides cloud-based software, customized AI, and AI consulting to a wide range of global clients.

This product has several features, including its low price (please inquire about the price), fast data updates (you can search for notifications from the previous day), and the display of the type of search being performed based on the user's prompt. In addition, since the LLM is tuned specifically for regulatory information, the hallucination is minimized and you can quickly access the desired information.

Richmond Pharmacology has over 20 years of experience conducting over 100 Phase-I trials in London targeting Japanese volunteers, and is a very unique CRO with the largest Japanese database (24,000 people) of any facility based in Europe, and has a track record of being used by many clients, particularly those planning international joint clinical trials. In addition, recently, trials targeting specific patient cohorts have accounted for approximately 60% of the total number of trials, and the company is also focusing on clinical trials in the fields of gene silencing and gene editing. While accurately grasping the needs of the times, the company is working hard to accelerate research using adaptive designs and provide "Faster Answers."

Saama’s mission is to improve lives by accelerating the delivery of therapies to patients.

Saama uses artificial intelligence (AI), along with advanced analytics, to automate key clinical development processes and surface actionable insights. This allows customers to accelerate their time to market and eliminate manual, resource-intensive processes.

Saama accomplishes this mission through the combination of our strong portfolio of SaaS-based solutions, ready for deployment out-of-the box, as well as our ability to work with your organization to build and deploy custom AI and advanced analytics-based solutions. This combination of capabilities means we can cover the entire spectrum of clinical development and commercialization.

Sequentia Biotech is a bioinformatics AI company that applies Omics data to various industries and environments such as healthcare, pharmaceuticals, and agriculture (for example, forest resources and water) through AI, and derives new insights by combining customers' data with Sequentia's Omics data. Headquartered in Barcelona, ​​the company provides cloud-based software, customized software, and bioinformatics consulting services to a wide range of global clients.

For the pharmaceutical industry, applications include designing personalized medicine and discovering new biomarkers using Omics data and clinical data (RWD and clinical trial data), but we believe that it can also be applied to agriculture, livestock farming, environmental science, and more.

The rights to individual trade names, trademarks, marks, logo marks, etc. on this website belong to our company or the rights holders who have authorized our company to use them. The use of these without the consent of the respective rights holders is prohibited by law, except as permitted by trademark law and other laws.